Biologic patent life emerges as sticking point in failed TPP talks

In the latest rounds of Trans-Pacific Partnership (TPP) talks in Maui, the 12 participating countries could not finalize an agreement, and pharmaceutical patents continued to be an area of contention. 

By Nicole Gray • Aug. 2, 2015

The Teva-Allergan deal and the power of the 'focus factor'

We spoke with DRG partner John Jaeger about what’s driving deals, including the recent Teva-Allergan agreement, in what he calls the "new era of U.S. healthcare."

By Nicole Gray • July 30, 2015

Welcome to the club: Regeneron, Sanofi to team up, join cancer immunotherapy fray

It's the hottest therapeutic space in oncology, and two huge players are getting into the game.

By Nicole Gray • July 29, 2015

Allergan buys Naurex for $560 million, nabs 2 antidepressants

The drugs gained in the deal are both intravenous NMDA receptor modulators.

By Nicole Gray • July 27, 2015

Teva to snap up Allergan's generics unit for $40.5B, become Big Pharma behemoth

The deal will put an end to the company's dogged pursuit of Mylan, catapult Teva into Big Pharma's upper echelons—and is bound to raise antitrust concerns.

By Nicole Gray • July 27, 2015

Tekmira to become Arbutus, shift focus to hep B

After Tekmira's merger with OnCore in March, the combined entity now boasts that largest hepatitis B (HBV) pipeline in the industry. 

By Nicole Gray • July 21, 2015

Innovation vs. access: The big drug battle in Trans-Pacific Partnership negotiations

The generics industry worries over the intellectual property provisions of the complex trade agreement.

By Nicole Gray • July 17, 2015

Celgene buying Receptos for $7.2 billion

The deal brings ozanimod -- a promising late-stage candidate with multiple potential applications -- into Celegene's portfolio.

By Nicole Gray • July 15, 2015

AstraZeneca divests gastro drug for $215 million

The drug will go to Tillotts Pharma. 

By Nicole Gray • July 10, 2015

Insurers are getting bigger—What does that mean for pharma's pricing power?

Credit rating giant Moody's suggests that the trend towards insurer consolidation could come at pharma's expense.

By Nicole Gray • July 9, 2015

CF Foundation gains massive windfall from Vertex's Kalydeco

A Bloomberg report highlights the massive financial gain the charity has enjoyed from the drug—in excess of $3 billion.

By Nicole Gray • July 8, 2015

Horizon Pharma in hostile pursuit of Depomed for $3 billion

It would be an all-stock deal.

By Nicole Gray • July 8, 2015

Teva plans to hike Mylan bid by $2B to $43 billion this week: report

Mylan wanted the Israeli pharma giant to put up an official takeover offer. The company may soon get its wish.

By Sy Mukherjee • July 7, 2015

Biogen pursuing AGTC's ophthalmology gene therapy—for up to $1 billion

It's a big deal for a portfolio of gene therapies to treat orphan eye diseases.

By Nicole Gray • July 7, 2015

Drug makers warn EU over troubled Greece: Medicine supply 'may be in jeopardy'

The industry is warning that the Greek drug-supply chain may be severely disrupted if Greece leaves the Euro zone. 

By Nicole Gray • July 2, 2015

'Innovation' is everywhere in biopharma—but what does that actually mean?

Innovation has many definitions. But it can’t exist without collaborative partnerships.

By Nicole Gray • July 2, 2015

AMAG Pharma to snap up stem cell firm for $700 million

The acquisition will give AMAG access to 600,000 preserved umbilical cord blood and tissue stem cell units, and is meant to bolster the company's maternal health ambitions.

By Isabella Alvarez • June 30, 2015

Novartis back in the pain game with $700M deal for Australia's Spinifex

The Australian company's investigational painkiller has a different mode of action compared to conventional opiates.

By Nicole Gray • June 30, 2015

Dutch or American? In takeover drama, Mylan seems to want it both ways

In February, Mylan completed a tax-inversion deal that relocated its corporate headquarters to the Netherlands.

By Nicole Gray • June 23, 2015

Teva completes Mylan share purchases, official takeover bid could come any day

Teva has now hit the 4.6% ownership threshold for Mylan.

By Nicole Gray • June 19, 2015

Despite insider sale, Receptos stock surges on takeover rumors

Lilly Ventures sold 25% of its holdings in Receptos last week, but the stock still moved up on whispers of an imminent takeover bid. 

By Nicole Gray • June 18, 2015

GSK's decision to cast off now-valuable drugs raises questions

Four drugs that GlaxoSmithKline (GSK) discarded are now valued at $5 billion. 

By Nicole Gray • June 17, 2015

Bayer, Johns Hopkins team up for eye disease R&D

The alliance hopes to find treatments to common causes for vision loss such as AMD and DMA.

By Nicole Gray • June 17, 2015

Abbott gets involved in M&A drama, backs Perrigo buy

The move means Mylan's bid has the backing of its largest shareholder.

By Nicole Gray • June 17, 2015

Study: Biopharma's pipeline-by-merger strategy isn't working

According to an analysis by the consulting firm McKinsey & Company, most companies forging licensing and acquisition deals have lost hit rates.

By Nicole Gray • June 17, 2015